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Introduction: Access to hepatitis C (hereafter HCV) antiviral therapy has commonly excluded populations with
mental health and substance use disorders because they were considered as having contraindications to treatment,
particularly due to the neuropsychiatric effects of interferon that can occur in some patients. In this review we
examined access to HCV interferon antiviral therapy by populations with mental health and substance use
problems to identify the evidence and reasons for exclusion.
Methods: We searched the following major electronic databases for relevant articles: PsycINFO, Medline, CINAHL,
Scopus, Google Scholar. The inclusion criteria comprised studies of adults aged 18 years and older, peer-reviewed
articles, date range of (2002–2012) to include articles since the introduction of pegylated interferon with ribarvirin,
and English language. The exclusion criteria included articles about HCV populations with medical co-morbidities,
such as hepatitis B (hereafter HBV) and human immunodeficiency virus (hereafter HIV), because the clinical
treatment, pathways and psychosocial morbidity differ from populations with only HCV. We identified 182 articles,
and of these 13 met the eligibility criteria. Using an approach of systematic narrative review we identified major
themes in the literature.
Results: Three main themes were identified including: (1) pre-treatment and preparation for antiviral therapy,
(2) adherence and treatment completion, and (3) clinical outcomes. Each of these themes was critically discussed in
terms of access by patients with mental health and substance use co-morbidities demonstrating that current
research evidence clearly demonstrates that people with HCV, mental health and substance use co-morbidities have
similar clinical outcomes to those without these co-morbidities.
Conclusions: While research evidence is largely supportive of increased access to interferon by people with HCV,
mental health and substance use co-morbidities, there is substantial further work required to translate evidence into
clinical practice. Further to this, we conclude that a reconsideration of the appropriateness of the tertiary health
service model of care for interferon management is required and exploration of the potential for increased HCV care
in primary health care settings.Introduction
The estimated global prevalence of HCV is approximately
130–170 million with regional variations [1]. Every year
around 3–4 million people are infected with HCV and
more than 350,000 people die from HCV [2]. HCV is a
major cause of morbidity and mortality due to liver disease
including inflammation, cirrhosis and hepatocellular car-
cinoma. The majority of people with HCV are injecting
drug users (IDUs) and a significant proportion of those* Correspondence: julie.hepworth@qut.edu.au
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reproduction in any medium, provided the orhave mental health problems [3,4]. Therefore, HCV in-
volves widespread psychosocial morbidity that can pre-
exist diagnosis, and be compounded by or result from the
diagnosis of HCV due to it being a life threatening disease.
As stated by Hirsch and Wright [5] (2003: 536), “Hepatitis
C is an insidious, slowly progressive killer”. The standard
treatment for HCV is combination therapy with peginter-
feron and ribavirin (hereafter interferon) with new direct
acting antiviral drugs becoming available for patients with
specific genotypes [6]. Because interferon is associated with
neuropsychiatric adverse effects [7], in earlier clinical prac-
tice from around the 1990s, patients with mental health
and substance use were often excluded from accessingral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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strate that such exclusion is no longer necessary except in
certain circumstances [9]. However, substantial increased
access to interferon by populations with mental health and
substance use problems has not been achieved to date. For
example, in Australia, only approximately 3,500 people per
year commence antiviral therapy, this figure is well below
the required 6,000 to stabilize the population from pro-
gressing to advanced liver disease [3], and potential adverse
health effects post treatment is a deterrent [10]. Therefore,
access to HCV treatment and health care services by popu-
lations with mental health and substance use problems is
complicated by a number of factors and barriers raising a
key issue about equity.
As the WHO (2007) maintains, health care systems
have a weak health equity orientation, are not pro-poor
and do not effectively address the health needs of margin-
alized groups [11]. In the case of HCV, treating patients
with HCV and mental health co-morbidity is already com-
plex, but is further compounded by inadequate health care
systems and service delivery. Furthermore, HCV popula-
tions can experience stigma and discrimination in both
health service use and in the community [12,13]. Com-
mon reasons for the exclusion of patients with HCV, men-
tal health and substance use problems to access antiviral
therapy include not only the possibility of psychiatric mor-
bidity, but concerns about lack of adherence to the inter-
feron regimen. In a recent study of physicians 48% refused
to treat HCV infected patients because of alcohol and
drug use, even though drug and alcohol use did not affect
sustained virological response, and 46% refused naming
mental health reasons as the barrier to treatment [14]. At
the primary care level only 39% of general practitioners
were highly likely to discuss psychosocial issues with
patients and 37% reported difficulty with having a cen-
tral role in the psychological and medical care of their
patients [15].
Therefore, given the complexity of issues involved with
HCV, mental health and access to antiviral therapy, we
aimed to develop a review summary that would inform
current directions for access to antiviral therapy and man-
agement of these vulnerable HCV populations. The main
objective of this paper was to provide an overview of the
main themes in the literature about HCV, mental health
and antiviral therapy from which a critical discussion
could be developed rather than an exhaustive systematic
review. The main research question was: How do mental
health and substance use co-morbidities affect access to
interferon therapy?
Method
Search strategy
We searched the following major electronic databases for
relevant articles: PsycINFO, Medline, CINAHL, Scopus,Google Scholar. The inclusion criteria comprised adults
aged 18 years and older, peer-reviewed articles, date range
of (2002–2012) to include articles since the introduction
of pegylated interferon with ribarvirin, and English lan-
guage. The exclusion criteria included articles about HCV
populations with medical co-morbidities, such as HBV
and HIV, because the clinical treatment, pathways and
psychosocial morbidity differ from populations with only
HCV. The search terms were “hepatitis C” AND “psy-
chosocial” AND “treatment” (and multiple variations
of search terms as listed in Appendix 1) and to ap-
pear anywhere in the title or abstract. To extend the
search for specific relevant articles we also used
snowball sampling to identify key articles from the
reference lists of articles we had already obtained. Ar-
ticles were eligible if they referred to populations who
were being considered for interferon therapy and who
had a mental health diagnosis or both a mental health
diagnosis and substance/alcohol use problems in the
title and/or abstract. The focus of the review was on
access to interferon antiviral therapy by these popula-
tions. The following types of articles were included:
original research, literature reviews, clinical reviews,
expert opinion and a consensus statement.
We organized the data according to its relationship to
access to antiviral therapy categorizing it into three main
areas: (1) preparation for antiviral therapy, (2) during
treatment and adherence to treatment, and (3) clinical
outcomes. These areas represented the major foci that
inform clinical practice around access to HCV antiviral
therapy. This categorization provided a framework with
which to critically discuss the literature and identify gaps
in research, health services and clinical practice. Narra-
tive review frameworks informed the review [16,17]. A
particular strength of meta-narrative review is that it en-
ables researchers to demonstrate how a phenomenon
has unfolded over time and the sorts of questions that
have been asked at particular points in time [16]. This
approach to a review was useful for the area of HCV,
mental health and access to treatment because it enabled
us to identify the complexities and barriers related to the
exclusion of people with mental health and/or substance
use problems from accessing antiviral therapy. By draw-
ing on work by Greenhalgh et al. [17] we used the six
phases in narrative review to guide a systematic ap-
proach to the selection and analysis of key literature in
the field, and summarise these phases in Table 1.
The multidisciplinary research team comprised a health
psychologist, an academic general practitioner, and a spe-
cialist HCV researcher and policy analyst. The team held
regular meetings to develop and refine the research ques-
tion, the search terms, discuss emerging findings and ana-
lyse key articles. The articles were read several times by
the authors, repeatedly checked for their relevance to the
Table 1 Summary of the phases in meta-narrative review (adapted from Greenhalgh et al. 2005)
Greenhalgh et al. [17] Adapted
1 Planning phase: assemble multidisciplinary team, establish regular
meetings.
→ Established multidisciplinary team.
→ Held regular team meetings.
2 Search phase: initial search led by intuition, search for seminal papers,
search for empirical papers.
→ Systematic search of major electronic databases.
→ Searched for seminal papers.
3 Mapping phase: identify key elements of research traditions, main
findings.
→ Identified key approaches to the problem of access to HCV
antiviral therapy.
→ Identified inconsistencies across approaches.
4 Appraisal phase: evaluation of each paper for relevance to the review
question, extract key results, group comparable results;
→ Evaluated each paper for relevance to the research question,
extracted key results and categorized comparable areas.
5 Synthesis phase: identify all key dimensions of the problem, give a
narrative account of each contribution, treat conflicting findings as
higher order data and explain;
→ Described each area with reference to included articles.
→ Critically discussed the areas and inconsistencies across the
articles.
6 Recommendations phase: summarise overall messages from the
research literature, distil and discuss recommendations
for practice, policy and further research.
→ Summarised and distilled key messages from the literature.
→ Made recommendations for developing clinical guidelines and
health service policy.
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lyses it was possible to identify key narratives and build a
consensus among the research team about the areas of
major interest in the literature (see Table 2 below). Subse-
quently, the research team critically discussed the findings
and formulated recommendations.
Results
The initial search retrieved 182 articles, 169 were ex-
cluded because they did not meet the inclusion criteria
or duplicated articles, resulting in a total of 13 included
articles (see Figure 1). These included literature reviews
(n = 3), clinical reviews/reports (n = 3), description of a
clinical model (n = 1), evaluation (n = 1), retrospective
chart review (n = 1), prospective study (n = 1), qualitative
research (n = 1), and consensus statement/conference
report (n = 2). All articles referred to populations with
mental health and substance use problems.
Three key areas were identified:
(1) Pre-treatment strategies/preparation for HCV
antiviral therapy.
Preparation for antiviral therapy included psycho-
education, comprehensive psychiatric/psychological
and medical screening and assessment, and the es-
tablishment of collaborative care [18,19]. The pe-
riods of time in preparation for HCV therapy
varied considerably from several weeks to several
months, and involved the delivery of programs that
had been specifically designed to prepare patients
for HCV antiviral therapy and/or the referral of pa-
tients between psychiatric and medical specialists
for assessment [18,20,21]. In the latter case, the
type of care that was provided was referred to as
multidisciplinary [18] but primarily involved amedical specialist located in a hospital who sought
mental health and substance abuse services in the
community as required rather than the involve-
ment of a multidisciplinary team from the outset of
management. This is important because integrated
multidisciplinary team care is argued to result in
more effective care, greater patient satisfaction and
reduces the risk of a dislocation of communication
and care coordination across hospital and commu-
nity based services.
(2) Adherence/completion of antiviral treatment.
Adherence to HCV medical regimens and the
completion of treatment by patients with mental
health and/or substance use problems have been
concerns in the HCV literature for over two
decades. The articles (n = 2) that focused on
adherence/completion of antiviral therapy
demonstrated that mental health and/or substance
use did not affect completion rates [22,23].
Additionally, this research prioritized engagement
with patients and easier access to health services
by HCV populations through community-based
settings such as drug and alcohol clinics resulting
in increased adherence and treatment completion.
(3) Clinical outcomes and health service delivery.
In terms of clinical outcomes, 6 articles make clear
conclusions that mental health and substance use
do not have a deleterious effect and outcomes were
comparable to populations without these co-
morbidities [8,24-28]. The major setting for the
management of HCV, mental health and antiviral
therapy was a hospital specialist outpatient liver
clinic in 8 articles [8,21,23-28], in 2 articles the
model of care was community-based [22,29], and
in 1 article [8] various settings were included. In
Table 2 Key narratives in research on HCV, mental health and antiviral therapy
Research focus Author Article type Primary purpose Outcomes/conclusion
Preparation for
HCV antiviral
Bonner et al.
[18]
Review of clinical
experience
This paper sought to highlight critical pre-
treatment strategies and provide tangible
resources for HCV clinicians to facilitate
preparation and successful treatment of
these patients.
HCV clinicians (gastroenterologists/
hepatologists) are in a unique position to
prepare patients with co-existing MH and/or
SA issues for antiviral therapy. Safely treat
these populations with multidisciplinary
care. Specialist, hospital clinicfocus.
Hong et al.
[19]
Clinical case
study
Case presentation of a 50 year-old man with
HCV and an extensive history involving
alcoholism,depression, and suicidiality who
participated in a psycho-education group to
help prepare him for treatment with pegy-
lated alpha/ribavirin interferon therapy.
Psycho-education groups show promise to
prepare patients for intensive medical
treatment. The challenge is to help patients
overcome barriers to treatment, particularly
psycho-social problems, because available
treatments are increasingly effective.
Rifai et al. [20] Literature Review
(1972-2009)
Review summary of the psychiatric
implications of HCV infection and strategies
for the management of interferon alfa-
induced neuropsychiatric adverse effects.
Interferon can be safely administered to
patients with psychiatric disorders provided
there is comprehensive pre-treatment as-
sessment, a risk-benefit analysis, and inten-
sive ongoing medical and psychiatric
follow-up.
Sylvestre &
Zweben [30]
Descriptive report Report of a peer-based HCV model to ad-
dress barriers to treatment intervention.
Peer-based model was successful at
engaging, educating, and treating drug
users and can facilitate their successful
screening and treatment
Knott et al.
[21]
Evaluation study Evaluation of the effect of integrating
psychiatric and medical care on evaluation
for and initiation of antiviral treatment.
An integrated MH and medical approach
was associated with rates of antiviral therapy
recommendation and initiation similar to
patients without risk for psychiatric or
substance use problems.
Adherence/
completion
antiviral therapy
Norman
et al. [22]
Research article Description of an evaluation of a peer-based
integrated model of care.
A high level of patient acceptability by
patients using the service.
Dollarhide
et al. [23]
Retrospective
chart review
To evaluate the impact of common
psychiatric disorders on treatment
completion of antiviral therapy prescribed to
a series of hepatitis C (virus) positive US
veterans.
Prior psychiatric or substance use history did
not predict completion of recommended
IFN/ribavirin treatment. Findings. suggest a
larger pool of veterans with psychiatric or
substance use disorders may be considered
for antiviral therapy when provided with
multidisciplinary support.
Clinical
outcomes
Schaefer
et al. [24]
Meeting report/EU
Consensus
statement
Summary of current knowledge of HCV
infection, antiviral treatment and mental
health.
The experience of the last 10 years has
clearly shown that patients with psychiatric
co-morbidity should not necessarily be ex-
cluded from IFN-a-based antiviral therapy.
Freedman &
Nathanson [25]
Literature review
(2003-2007)
Review of evidence-based best clinical prac-
tice of HCV with IFN-based therapy in pa-
tients with severe mental illness (SMI) and
substance use disorders (SUDs).
clinical outcomes comparable with those
without these comorbidities.
Schaefer et al.
[26]
Prospective study Investigated and compared the results of
treating the chronic hepatitis C (HCV)
infection of different groups of psychiatric-
risk patients and controls with pegylated
interferon alpha plusribavirin.
Psychiatric diseases and/or drug addiction
did not negatively influence psychiatric
tolerability of and antiviral response rate to
HCV treatment with pegylated interferon
alpha plus ribavirin.
Mistler [27] Clinical case
report
Report on three patients with hepatitis C
infection, severe mental illness, and
substance use disorders.
Patients were successfully treated for
hepatitis C (cleared the virus) with carefully
monitoring and psychiatric oversight.
Sylvestre et al.
[28]
Conference
report
Summarises current management issues. Selected substance users can be candidates
for HCV treatment even in the setting of
psychiatric disease and relapse to drug use.
Loftis &
Hauser [8]
Review Examines co-management models of care
for HCV patients with psychiatric and sub-
stance use.
Many patients with comorbid use diagnoses
can be treated safely and
effectivelypsychiatric and substance with
co-management strategies.
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Medline: 
     57 
Cinahl: 16 Scopus: 66
Total N=182
169 Excluded
(duplicate or did 
not meet criteria) 
13 Included
PsychINFO:
        43 
Figure 1 Literature searching strategy.
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[19] models of care was not relevant, and the con-
sensus statement on HCV, mental health and anti-
viral therapy did not address models of health
service delivery [24]. Multidisciplinary teams were
reported in all articles and their composition
ranged from the inclusion of a psychiatrist in the
liver clinic for routine psychiatric assessment pre
and during treatment through to broader teams
that included any or all of the following: liver spe-
cialist, an addiction specialist, primary care phys-
ician/general medical practitioner, nurse, and HCV
peer worker. The broader multidisciplinary team
composition was evident in 9 [8,18-23,27,30] of the
13 articles.Discussion
This review has identified emerging research evidence that
overall populations with mental health and substance/
alcohol use problems can and should have similar access
to interferon as populations who do not have these co-
morbidities. In contrast to some clinical practices that
have excluded populations with mental health and/or sub-
stance use problems from accessing interferon therapy,
this review provides clear evidence based on original re-
search, clinical observations and clinical reviews that these
populations can be safely treated in a multidisciplinary
care context [18-20,24,27,28,30], that prior psychiatric or
substance use history does not predict completion of IFN/
ribavirin treatment [23], and that clinical outcomes are
comparable with those without these co-morbidities [25].
Of particular note is the recent European Expert Consen-
sus statement [24] that maintains patients with pre-
existing disorders can be treated with interferon based
regimens and do not have an increased poor compliance,
lower SVR, more severe depression during treatment or
treatment failure. This finding is supported by some clin-
ical guidelines for the management of HCV patients [9].This evidence has fundamental implications for equity in
relation to patient access to health care, for health profes-
sionals, for the implementation of clinical guidelines for
HCV management, and for health system change. Having
clear evidence to support such widespread increased access
to interferon, however, is not always translated into clinical
practice. A number of reasons may account for the lack of
evidence-based practice, including clinicians’ entrenched
beliefs about populations with mental health/substance use
problems being barriers to effective treatment, discrimin-
ation, economic considerations, lack of appropriate health
service delivery and poor patient engagement.
Unlike the requirement that interferon commence-
ment is conditional upon demonstrable improvement in
patients’ mental health and/or abstinence from alcohol/
substance use, in the above studies interferon was com-
menced within a period ranging from several weeks or
months. This demonstrates a shortening of the length of
time for treatment to commence from what was typically
6 months. During this period comprehensive pre-HCV
therapy strategies were employed involving one or more
of the following: (1) mental health and substance use
screening and assessment, (2) HCV/IFN information, edu-
cation and support, and (3) establishment of multidiscip-
linary care [18-20,22-25,27,28,30]. Comprehensive regular
monitoring was continued during and post interferon
therapy. In cases where there was uncontrolled major
depression adequate symptom remission was necessary
prior to commencing interferon therapy [23]. These stud-
ies demonstrate a different approach to patient access to
interferon whereby on participation in or completion of a
clearly defined pre-therapy preparatory program patients
progress to commence therapy. Therefore, there is consid-
erable variation across different global regions regarding
the clinical requirement for some degree of remediation
or rehabilitation from the patient in order to receive treat-
ment. This suggests a need for changing some clinicians’
values and perceptions of these population groups to en-
able both an increase in the expansion of access to inter-
feron treatment and earlier commencement of treatment.
The most common health care setting in which inter-
feron was managed in the above studies was a specialist
clinic in a major tertiary hospital. All studies refer to a
multidisciplinary and/or integrated model of care for the
management of interferon with patients with mental
health and substance/alcohol use problems largely com-
prising, however, only a gastroenterologist or HCV/liver
specialist and a psychiatrist [18,19,23,24,27]. In the study
by Dollarhide et al. [23] the multidisciplinary team was
expanded to include an addiction specialist. The study
by Rifai et al. [20] was the only one to report inclusion
of a primary care physician.
Primary care generally provides low threshold, highly
accessible and multidisciplinary comprehensive care with
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agement. It could therefore be an ideal environment to
ensure management of chronic care services to vulner-
able population groups such as HCV patients. However,
the only other model of HCV interferon management
identified was community based health care located in
drug and alcohol clinics. In the study by Norman et al. [22]
they demonstrate that it is feasible to provide a quality
HCV treatment service that had a high acceptability to
substance using clients. The integrated multidisciplinary
team included primary care medical practitioners, a visiting
specialist liver physician, peer worker, nurse, pharmacist
and allied health as required. Similarly, Sylvestre et al. [28]
maintain that interferon treatment can be successfully inte-
grated into health care settings that provide care for popu-
lations with mental health and substance use problems
such as methadone clinics, prisons and community-based
‘walk-in’ clinics. Arora et al. [29] have combined integrated
multidisciplinary care with videoconferencing to establish
and increase access to HCV care in marginalized commu-
nities with significant improvements in providers’ experi-
ences of care delivery. Finally, Sylvestre and Zweben [30]
report positive outcomes from a community-based pro-
gram based on collaboration between medical providers
and peer educators whereby the meaningful engagement of
IDUs enabled screening and HCV treatment resulting in
further positive effects on adherence. Currently, there ap-
pears to be some emerging randomized controlled trials of
integrated care such as those by Evon et al. [31] and
Groessl et al. [32] but these are restricted to major medical
centres, and there is little focus on the potential of
integrated multidisciplinary care of HCV management in
primary health care settings. The emerging studies of
community-based models of health care for interferon
management were restricted to injecting drug user settings
and no studies involving general practice were identified.
Indeed, there is a paucity of research on the potential for
interferon to be managed in general practice or other pri-
mary care settings. General practitioners, however, are re-
portedly not confident to initiate therapy, but do have an
interest in education about HCV antiviral therapy [33]
demonstrating the need for more research investment into
their education and service development needs.
The dominance of hospital managed HCV antiviral treat-
ment clearly serves as a major barrier to the populations
most affected by HCV; people with mental health and
substance use co-morbidities. The research evidence sug-
gests that for these populations it is imperative to establish
their engagement through community-based clinics run by
broad-based multidisciplinary teams. Therefore, we identi-
fied in this review an inverse relationship between the type
of health service model best suited to HCV, mental health
and substance use populations and what is actually avail-
able as the dominant model of care. The hospital specialistmodel was designed around the needs and convenience of
medical specialists rather than those of the population
groups and patient-centric care. We acknowledge that new
medicines such as those on their way for HCV require spe-
cialist oversight when introduced, but for the majority of
HCV populations this is not the case. The prior example
of the transition of the management of insulin initiation
away from hospitals and towards community-based clinics
serves as an analogy for what we observe is unfolding in
the area of HCV. In terms of models of service delivery,
the Beacon practice model [34], could be a framework for
innovative HCV health service research to address in-
creased access. As part of future models of HCV manage-
ment it is also necessary to consider the introduction of
interferon free HCV antiviral treatment regimens. How-
ever, given the current speculation about the timing of the
availability of new HCV medications interferon may well
continue to be the major treatment for some time yet, al-
though the prescribing practice will be of significant inter-
est in terms of access and equity.
This review drew on guiding principles of narrative
review and in so doing involved searching the inter-
national literature. One of the limitations of the review
was that the term ‘psychosocial’ was particularly prob-
lematic for a review using systematic principles because
it has several different meanings in the HCV literature.
Three particular types of use of the term ‘psychosocial’
were identified; first, it is used as an overarching term
for one or more psychiatric/psychological diagnoses, and
specifically, anxiety, depression, schizophrenia, psychosis,
and co-morbidity of diagnoses. Second, in many articles
mental health diagnoses were referred to as ‘psychiatric’
whereas ‘psychosocial’ referred to socio-economic status,
unemployment, poor social support and even “chaotic liv-
ing”. Third, in some articles mental health diagnoses were
included within the term psychosocial together with socio-
economic factors. Further to this, our search resulted in
only 13 eligible articles and 2 of these were conference re-
ports. Consequently, the extent to which the review iden-
tified the current evidence on HCV, mental health and
access to interferon remains relatively opaque.
Recommendations
The promising early results emerging from community-
based multidisciplinary care indicate that it would be
timely to explore multidisciplinary, integrated interferon
management in primary care. The potential benefits of
this model of care are threefold; First, it would create a
shift away from hospital-based health service delivery to-
ward primary health care as the driver of service
provision together with specialist input consistent with
international health policy reforms [35,36]. Second, the
reorientation of health service delivery is likely to result
in considerable cost savings. Third, the expansion of
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tate increased equity and access to health services for
marginalized populations.
So what is required to create such a change in health
service delivery that could increase equity of access to
interferon? First, general practitioners need to be moti-
vated, educated and supported to lead comprehensive
HCV treatment including interferon management in
close collaboration with liver and mental health special-
ists. Second, there needs to be a systematic exploration
of models of multidisciplinary, integrated care in the
community-based setting to determine what constitutes
quality, safety and the most cost effective model to
manage the multiple psychosocial and medical needs of
HCV patients. Third, patient engagement is crucial to
any successful expansion of access to interferon through
community-based services. This involves regular, exten-
sive and well-informed interaction with HCV popula-
tions that builds trust between clinic staff and patients
through which patients are prepared for interferon ther-
apy, its potential side effects, adherence, and also the
possibility of treatment failure.Conclusion
This review of access to HCV antiviral therapy by popula-
tions with mental health and substance use co-morbidities
illustrates that there are very few clinical contraindications
to treatment commencement, and, therefore, an increased
number of people with HCV could be receiving treatment.
Current evidence-based guidelines recommend inclusive
access to treatment. However, while there is evidence of a
changing perspective in this area, several barriers to in-
creasing access to interferon continue to exist. It is con-
cluded that a concerted effort to research and trial health
service development in primary health care settings for
the management of HCV antiviral therapy may be benefi-
cial for increasing patient access, treatment completion
and contribute to a more equitable health system designed
around the needs of patient-centred care.Appendix 1
Barrier terms
barrier* OR deffer* OR coexisiting OR co-exisiting OR vul-
nerabl* OR obstacle* OR psycho* OR withhold OR “with
hold” OR withheld OR “with held” OR decline* OR “non
treatment” OR “not treat*” OR contraindicat* OR uptake*
OR “up take” OR access* OR untreated OR “non attend-
ance” OR “non referral*” OR marginal* OR “social implica-
tion*” OR homeless OR “home less” OR stigma OR refus*
OR problem* OR “social implication*” OR stigma* OR
equity OR socio* OR co-occuring OR coexisiting OR com-
plex* OR challeng* OR socioeconomic OR finance OR
“mental health” OR anxi* OR depress*.Treatment terms
(treat* OR antiviral OR therap* OR interferon OR pro-
gram* OR educat*).
Hepatitis terms & subject headings
HCV OR “hepatitis C” OR “hep C
(MH “Hepatitis C”) OR (MH “Hepatitis C, Chronic”).
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